Citation Impact
Citing Papers
Targeting both HIF-1 and HIF-2 in human colon cancer cells improves tumor response to sunitinib treatment
2009
Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma
2005 Standout
Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor
2008
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
2007 Standout
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
EGFR Antagonists in Cancer Treatment
2008 Standout
Sunitinib in Patients With Metastatic Renal Cell Carcinoma
2006
Tumour–host interactions: implications for developing anti-cancer therapies
2006
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
2009 Standout
The role of FLT3 in haematopoietic malignancies
2003
Hepatocellular carcinoma
2018 Standout
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
2011 StandoutNature
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
TGF-β signalling-related markers in cancer patients with bone metastasis
2008
Inhibition of RET tyrosine kinase by SU5416
2006
Cancer drug resistance: an evolving paradigm
2013 Standout
Ranibizumab for Neovascular Age-Related Macular Degeneration
2006 Standout
HIF2α cooperates with RAS to promote lung tumorigenesis in mice
2009 StandoutNobel
Angiogenesis and antiangiogenic therapy in hematologic malignancies
2006
New insights into nNOS regulation of vascular homeostasis
2005 StandoutNobel
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
2011 Standout
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
2007 Standout
Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways
2005 StandoutNobel
Expression of Vascular Endothelial Growth Factor Receptor 1 in Bone Marrow-derived Mesenchymal Cells Is Dependent on Hypoxia-inducible Factor 1
2006 StandoutNobel
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
2006 Standout
Tumor-Associated Macrophages: From Mechanisms to Therapy
2014 Standout
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition
2007
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
2013 Standout
Innovations and challenges in renal cancer: Summary statement from the Third Cambridge Conference
2009 StandoutNobel
The Molecular Basis of Leukemia
2004
Nasopharyngeal carcinoma
2015 Standout
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
2005 Standout
Evading tumor evasion: Current concepts and perspectives of anti-angiogenic cancer therapy
2010
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors
2007
Mesoporous Silica Nanoparticles: Synthesis, Biocompatibility and Drug Delivery
2012 Standout
Molecular genetics in acute myeloid leukemia
2010
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
2007 Standout
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
2011 Standout
Switching on kinases: oncogenic activation of BRAF and the PDGFR family
2004
Molecular basis for sunitinib efficacy and future clinical development
2007
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
2013 Standout
Mitigation of cardiovascular toxicity in a series of CSF-1R inhibitors, and the identification of AZD7507
2013
Benefit-Risk Assessment of Sunitinib in Gastrointestinal Stromal Tumours and Renal Cancer
2009
Microenvironmental regulation of metastasis
2008 Standout
Targeting tumor–stromal interactions in bone metastasis
2013
Molecular Genetic Pathways as Therapeutic Targets in Acute Myeloid Leukemia
2008
Tumor metastasis: mechanistic insights and clinical challenges
2006 Standout
Targeting Immunosupportive Cancer Therapies: Accentuate the Positive, Eliminate the Negative
2007 StandoutNobel
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
2011 StandoutNobel
Astrocyte–endothelial interactions at the blood–brain barrier
2005 Standout
Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype
2012
Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure
2009
Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma
2010
Angiogenesis as a therapeutic target
2005 StandoutNature
Tumor Angiogenesis
2008 Standout
The management of brain edema in brain tumors
2004
The cancer genome
2009 StandoutNature
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Hepatocellular Carcinoma
2019 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Acute Myeloid Leukemia
2015 Standout
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
2004 Standout
Emerging nanomedicine approaches fighting tumor metastasis: animal models, metastasis-targeted drug delivery, phototherapy, and immunotherapy
2016
Tyrosine Kinases as Targets for Cancer Therapy
2005
Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors
2008
Inhibition of Natural Type I IFN-Producing and Dendritic Cell Development by a Small Molecule Receptor Tyrosine Kinase Inhibitor with Flt3 Affinity
2005
Flt3 permits survival during infection by rendering dendritic cells competent to activate NK cells
2010 StandoutNobel
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
2009 Standout
Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?
2006
Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer
2008
After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies
2004
Sunitinib: From Rational Design to Clinical Efficacy
2007
Stromal Cell–Derived Factor-1α and CXCR4 Expression in Hemangioblastoma and Clear Cell-Renal Cell Carcinoma: von Hippel-Lindau Loss-of-Function Induces Expression of a Ligand and Its Receptor
2005 StandoutNobel
Innovations and Challenges in Renal Cell Carcinoma: Summary Statement from the Second Cambridge Conference
2007 StandoutNobel
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease
2005
Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer
2005
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
2003
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Applications of Palladium-Catalyzed C–N Cross-Coupling Reactions
2016 Standout
Hypoxic retinal Müller cells promote vascular permeability by HIF-1–dependent up-regulation of angiopoietin-like 4
2013 StandoutNobel
FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases.
2003
Comparative Analysis of Mutant Tyrosine Kinase Chemical Rescue
2009 StandoutNobel
Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
2009
The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond
2014
Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
2013
Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
2008
The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease
2006 StandoutScience
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications
2004
Works of A O’Farrell being referenced
SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model
2003
SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase
2002
An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.
2003
A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia
2003
A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657
2003